CALCA and migraine disorder: In Japan, erenumab is approved for the “prevention of migraine attacks.” In this case, given the patient's history of episodic migraine, continuous migraine-like symptoms, and sustained response to CGRP-targeted therapy, her clinical presentation was considered to share characteristics of both NDPH and chronic migraine with continuous daily headache.